SCHEMBL4930867

SCHEMBL4930867

CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc3[nH]c(C(=O)O)c(-c4ccc(O)cc4)c3c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UQCRB P14927 3/20 0.56
BRD4 O60885 1/20 0.54
PTPN5 P54829 1/20 0.53
SERPINE1 P05121 1/20 0.49
GAA P10253 2/20 0.45
AR P10275 1/20 0.45
PKM P14618 1/20 0.45
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
ALDH1A1 P00352 4/20 0.45
MAPT P10636 2/20 0.45
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
GPR35 Q9HC97 1/20 0.44
HDAC3 O15379 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
GFER P55789 2/20 0.44
GSK3A P49840 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3947323 0.92 BRD4 (0.54) UQCRBBRD4PTPN5SERPINE1GAA
SCHEMBL3945167 0.92 BRD4 (0.61) UQCRBBRD4PTPN5SERPINE1MEN1
SCHEMBL3946651 0.91 BRD4 (0.53) UQCRBBRD4PTPN5SERPINE1GAA
SCHEMBL4933597 0.91 GPR35 (0.53) UQCRBBRD4PTPN5SERPINE1GAA
SCHEMBL4933945 0.90 MAPT (0.59) UQCRBBRD4PTPN5SERPINE1GAA
Dimethylamine SCHEMBL4931369 0.90 BRD4 (0.59) UQCRBBRD4PTPN5SERPINE1MEN1
SCHEMBL4934791 0.90 UQCRB (0.57) UQCRBBRD4PTPN5SERPINE1GAA
SCHEMBL3950737 0.90 MEN1 (0.58) BRD4PTPN5SERPINE1GAAPKM
SCHEMBL4931366 0.90 BRD4 (0.52) UQCRBBRD4PTPN5SERPINE1GAA
SCHEMBL3949114 0.89 BRD4 (0.53) UQCRBBRD4PTPN5SERPINE1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US claimed
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE NGUYEN DUY 2008-01-03 US disclosed
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY2, ADCY5 UQCRB 2466/4885BRD4 3928/4885PTPN5 1567/4885
US-20060074084-A1 Inhibitors of soluble adenylate cyclase ADCY1, ADCY2, ADCY5 UQCRB 2466/4885BRD4 3928/4885PTPN5 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.